Accelerating Oncology Trials: START and Advarra Unite to Enhance Efficiency and Quality
The START Center for Cancer Research (START), a renowned early-phase oncology research network, has officially partnered with Advarra, a leading provider of clinical research solutions. This collaboration aims to revolutionize early-phase oncology trials by integrating advanced regulatory and technological solutions offered by Advarra, ultimately enhancing efficiency, quality, and predictability for clinical trials.
In today's fast-paced medical environment, oncology drug development companies are under immense pressure to bring new and effective treatments to market quickly. The key to their success is often found in the efficacy of clinical trials, which must navigate a complex landscape of regulatory requirements, patient needs, and institutional protocols. By forming this strategic alliance, START and Advarra are set to create a more streamlined and interconnected ecosystem for potential breakthrough therapies.
Advarra will serve as START's preferred provider for Independent Review Board (IRB) and Institutional Biosafety Committee (IBC) services. START is also leveraging Advarra's OnCore Clinical Trial Management System (CTMS), which is widely recognized across over 85% of NCI-designated cancer centers. This partnership will utilize the integrated electronic regulatory management system known as eReg to ensure secure management of regulatory documents at all trial sites. This deployment is expected to bring standardized workflows and improve operational efficiency across the entire network of sites participating in the trials.
Nick Slack, MBE, CEO of START, emphasized the importance of this partnership, stating that the collaboration aims to combine cutting-edge technology and profound regulatory expertise to significantly enhance operational efficiency and patient safety. The new system not only accelerates the delivery of new therapies but ensures that the highest standards in patient care are met.
The ongoing implementation of Advarra's integrated solutions demonstrates START's commitment to innovation and excellence in oncology research. Existing systems such as OnCore and Advarra's IRB and IBC services will already be in active use, marking this partnership as a milestone in advancing operational capabilities within START’s network.
START focuses on community-based cancer trials, providing patients with access to specialized preclinical and early-phase clinical trials of novel therapies. With a record of more than 1,000 early-phase trials conducted, START's extensive experience positions it at the forefront of cancer research, aiming to connect patients with potential life-saving therapies. Meanwhile, Advarra’s role in dismantling traditional barriers to clinical research allows for a more collaborative and transparent understanding between patients, sites, sponsors, and Contract Research Organizations (CROs).
Both START and Advarra share a mission: to deliver hope and cutting-edge treatments to their patients while upholding stringent compliance and operational excellence. As they embark on this new chapter together, the oncology research community can expect a significant transformation in how clinical trials are conducted, ultimately benefiting patients worldwide. The partnership underscores the belief that innovation in clinical research can lead to quicker access to essential treatments—demonstrating a commitment to 'Hope Through Access' for all involved in the journey from trial to treatment.
For more on the START Center for Cancer Research, visit their website at STARTresearch.com. To learn more about Advarra and their services, head over to advarra.com.
In today's fast-paced medical environment, oncology drug development companies are under immense pressure to bring new and effective treatments to market quickly. The key to their success is often found in the efficacy of clinical trials, which must navigate a complex landscape of regulatory requirements, patient needs, and institutional protocols. By forming this strategic alliance, START and Advarra are set to create a more streamlined and interconnected ecosystem for potential breakthrough therapies.
Advarra will serve as START's preferred provider for Independent Review Board (IRB) and Institutional Biosafety Committee (IBC) services. START is also leveraging Advarra's OnCore Clinical Trial Management System (CTMS), which is widely recognized across over 85% of NCI-designated cancer centers. This partnership will utilize the integrated electronic regulatory management system known as eReg to ensure secure management of regulatory documents at all trial sites. This deployment is expected to bring standardized workflows and improve operational efficiency across the entire network of sites participating in the trials.
Nick Slack, MBE, CEO of START, emphasized the importance of this partnership, stating that the collaboration aims to combine cutting-edge technology and profound regulatory expertise to significantly enhance operational efficiency and patient safety. The new system not only accelerates the delivery of new therapies but ensures that the highest standards in patient care are met.
The ongoing implementation of Advarra's integrated solutions demonstrates START's commitment to innovation and excellence in oncology research. Existing systems such as OnCore and Advarra's IRB and IBC services will already be in active use, marking this partnership as a milestone in advancing operational capabilities within START’s network.
START focuses on community-based cancer trials, providing patients with access to specialized preclinical and early-phase clinical trials of novel therapies. With a record of more than 1,000 early-phase trials conducted, START's extensive experience positions it at the forefront of cancer research, aiming to connect patients with potential life-saving therapies. Meanwhile, Advarra’s role in dismantling traditional barriers to clinical research allows for a more collaborative and transparent understanding between patients, sites, sponsors, and Contract Research Organizations (CROs).
Both START and Advarra share a mission: to deliver hope and cutting-edge treatments to their patients while upholding stringent compliance and operational excellence. As they embark on this new chapter together, the oncology research community can expect a significant transformation in how clinical trials are conducted, ultimately benefiting patients worldwide. The partnership underscores the belief that innovation in clinical research can lead to quicker access to essential treatments—demonstrating a commitment to 'Hope Through Access' for all involved in the journey from trial to treatment.
For more on the START Center for Cancer Research, visit their website at STARTresearch.com. To learn more about Advarra and their services, head over to advarra.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.